We are excited to share the publication by Ingels J., De Cock L.,et al.in Cell Reports Medicine, reporting the results of a phase 1 clinical trial evaluating a neoantigen-targeted dendritic cell vaccine (Neo-mDC) in lung cancer patients. CellGenTherapies had a pivotal role in advancing this highly personalized cancer vaccine to its first-in-human clinical trial. Neo-mDC…